Chemical Properties
| form | Liquid |
| color | Colorless to light yellow |
Cetrelimab Chemical Properties,Usage,Production
Uses
Cetrelimab (JNJ 63723283; JNJ 3283) is a human IgG4κ mAb targeting PD-1. Cetrelimab binds PD-1 (Kd=1.72 nM, HEK293) to block the interaction of PD-1 with PD-L1 and PD-L2 (IC50s=111.7 ng/mL and 138.6 ng/mL, respectively). Cetrelimab stimulates peripheral T cells, increases IFN-γ, IL-2, TNF-α level and inhibits tumor growth in vivo[1].in vivo
Cetrelimab (10 mg/kg; i.p.; single dose) has antitumor efficacy, and decreases tumor volume in PD-1 knock-in (hPD-1KI) mice with MC38 tumor[1].
Cetrelimab (10 mg/kg; i.p.; once every 5 days for 30 d) results significant increases in peripheral blood CD8+ T cells in patient-derived xenograft (PDX) lung model in mice[1].
Cetrelimab (10-100 mg/kg; i.v.; once weekly for 5 weeks) has well tolerance in cynomolgus model[1].
Cetrelimab (0.1-10 mg/kg; i.v.; single dose, monitored for 57 d) shows an nonlinear pharmacokinetics (PK) in cynomolgus, possibly attributable to target-mediated drug deposition (TMDD)[1].
| Animal Model: | hPD-1KI model with mouse PD-1 ECD replaced by the human PD-1 ECD[1] |
| Dosage: | 10 mg/kg |
| Administration: | Intraperitoneal injection; single dose at day 7 after tumor implantation |
| Result: | hPD-1KI mice develop normally and have no immune abnormalities. Significantly lowered tumor volume at Day 21. |
| Animal Model: | Patient-derived xenograft (PDX) LG1306 lung model in mice[1] |
| Dosage: | 10 mg/kg |
| Administration: | Intraperitoneal injection; every 5 days for 6 cycles |
| Result: | Significantly reduced patient-derived tumor volume by 32%. |
| Animal Model: | Good Laboratory Practice (GLP) toxicity study in cynomolgus[1] |
| Dosage: | 0, 10, 30, or 100 mg/kg |
| Administration: | Intravenous injection; once weekly for 5 weeks |
| Result: | Showed well tolerance in cynomolgus. |
References
[1] DeAngelis N, et al. Discovery and pharmacological characterization of cetrelimab (JNJ-63723283), an anti-programmed cell death protein-1 (PD-1) antibody, in human cancer models. Cancer Chemother Pharmacol. 2022 Apr;89(4):515-527. DOI:10.1007/s00280-022-04415-5Cetrelimab Suppliers
Global(21)Suppliers
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| 027-65317797 15926423062 | 422450190@qq.com | 10300 | 58 | ||
| 177-54423994 17754423994 | 2853530910@QQ.com | 7999 | 62 | ||
| 13720134139 086-15871494362 13720134139 | orders@jknbiochem.com | 7353 | 58 | ||
| 15111215862 18229892877 | 3062105966@qq.com | 5580 | 58 | ||
| 15817493340 | 981810490@qq.com | 1577 | 58 | ||
| 027-65279366 18108604356 | products@biolabreagent.com | 9864 | 58 | ||
| 17316404525 17316404525 | 209533805@qq.com | 9790 | 58 | ||
| 021-65675885 18964387627 | customer_service@efebio.com | 11963 | 58 | ||
| 0573-83568680 18057391398 | 3956524501@qq.com | 1441 | 58 | ||
| 027-87008169 17762441161 | info@atagenix.com | 9997 | 58 |